DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
Prostate Cancer – Current Treatment – Current Treatment: Physician Insights – Prostate Cancer (US)
Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with ADT serving as the universal backbone. ARPIs—enzalutamide, apalutamide, and…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)
The treatment of non-nasopharyngeal SCCHN is heterogeneous and guided by multiple factors, such as tumor burden and growth, the line of therapy, and prior treatment exposure. In the locoregionally…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Treatment Sequencing – Squamous Cell Carcinoma of the Head and Neck (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Breast Cancer – Current Treatment – Current Treatment: Physician Insights – Breast Cancer (US)
The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy, are established…
